Approved for use through 11/30/2020. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Substitute for form 1449/PTO
`_
`
`Complete if Known
`
`—1e/474,461
`INFORMATION DISCLOSURE —December28e 20”
`First Named Inventor
`GARCIA COLLAZO, Ana Maria
`MW
`1629
`To Be Assigned
`Attorney Docket Number
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`.—
`
`4315.0020001/TJS/THN
`BOURQUE; Elyse etal.
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`Document Number
`
`Number-Kind Code2 (“WW")
`
`U. S. PATENT DOCUMENTS
`Publication Date
`Name of Patentee or
`MM-DD-YYYY
`Applicant of Cited Document
`
`Pages, Columns, Lines, Where
`Relevant Passages or Relevant
`Figures Appear
`
`us-7737153-32
`
`06-15-2010
`
`FEURER;Achim etal.
`
`US-20160207933-A1
`
`07-21-2016
`
`
`
`Examiner
`Initials*
`
`
`
`A. oear
`
`Pages,
`Columns,
`Lines,
`Where
`Relevant
`Passages
`Or Relevant
`Figures
`
`03
`
`FOREIGN PATENT DOCUMENTS
`
`Foreign Patent Document
`
`Publication
`Date
`MM-DD-YYYY
`
`Name of Patentee or
`Applicant of Cited Document
`
`Cite No.1
`
`Country Codez'NumberA'Kind Code5 (if known)
`
`
`
`
`FP1 WO-2004039796-A1
`
`05-13-2004
`
`BAYER HEALTHCARE AG
`[DE], et al_
`
`FP2 WO-2004039797-A1
`
`05-13-2004 CHENG JINGCAI [CN], et al.
`
`FP3 WO-2006110763-A1
`
`FP4 WO-2011049737-A1
`
`FP5 WO-2012035055-A1
`
`BAYER PHARMACEUTICALS
`10-19-2006 CORP [US], et a"
`
`04-28-2011
`
`AMICUS THERAPEUTICS
`INC [US], et a"
`
`03-22-2012
`
`GLAXO GROUP LTD [GB], et
`al.
`
`FP6 WO-2016168420-A1
`
`10-20-2016
`
`BIOMARIN PHARM INC [US]
`
`Examiner
`Signature
`
`Date
`Considered
`
`1
`2
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
`considered. Include copy of this form with next communication to applicant. Applicant’s unique citation designation number (optional). See Kinds Codes of USPTO Patent
`
`Documents at wwwus tto. c-v or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). A For Japanese patent documents, the
`indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the
`document under WIPO Standard ST.16 if possible. 6Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by
`37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application
`form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this
`burden, should be sent to the Chief Information Officer, US. Patent and Trademark Office, PO. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED
`FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.0. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`

`

`Approved for use through 11/30/2020. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`SubstItute for form 1449/PTO
`_
`
`Complete if Known
`
`—16/474,461
`INFORMATION DISCLOSURE —December28e 20”
`First Named Inventor
`GARCIA COLLAZO, Ana Maria
`MW
`1629
`To Be Assigned
`Attorney Docket Number
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`.—
`
`FOREIGN PATENT DOCUMENTS
`
`Examiner
`Initials*
`
`Foreign Patent Document
`
`Cite No.1
`
`-
`5
`-
`47
`37
`Country Code Number Kind Code (If known)
`
`
`
`
`
`FP7 WO-2018122775-A1
`
`FP8 WO-2002046172-A2
`
`FP9 WO-2003062225-A1
`
`FP10 WO-2007031529-A1
`
`FP11 WO-2009038695-A1
`
`07-05-2018
`
`06-13-2002
`
`07-31-2003
`
`03-22-2007
`
`03-26-2009
`
`FP12 WO-2012177997-A1
`
`12-27-2012
`
`FP13 WO-2013059119-A1
`
`04-25-2013
`
`FP14 WO-2013148103-A1
`
`10-03-2013
`
`FP15 WO-2016073895-A1
`
`05-12-2016
`
`FP16 WO-2015014900-A1
`
`02-05-2015
`
`FP17 WO-2016120808—A1
`
`08-04-2016
`
`El
`
`E
`
`MINORYX THERAPEUTICS S
`L [ES]
`
`[Ca/SIHERAPEUTICS’ INC'
`
`BAYER CORPORATION [US]
`
`PALAU PHARMA, S.A. [ES]
`THE HOSPITAL FOR SICK
`
`CHILDREN [CA]
`THE GENERAL HOSPITAL
`
`CORPORATION [US]
`THE REGENTS OF THE
`UNIVERSITY OF MICHIGAN
`AMICUS THERAPEUTICS
`
`[US]
`LYSOSOMAL
`
`THERAPEUTICS INC [US]
`MINORYX THERAPEUTICS
`S.L.
`MINORYX THERAPEUTICS
`S.L.
`
`4315.0020001/TJS/THN
`A. oear
`
`Publication
`Date
`MM-DD-YYYY
`
`Name of Patentee or
`Applicant of Cited Document
`
`Pages,
`Columns,
`Lines,
`Where
`Relevant
`Passages
`Or Relevant
`Figures
`
`
`
`Examiner
`Signature
`
`Date
`Considered
`
`1
`2
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
`considered. Include copy of this form with next communication to applicant. Applicant’s unique citation designation number (optional). See Kinds Codes of USPTO Patent
`
`Documents at wwwus tto. CV or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). A For Japanese patent documents, the
`indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the
`document under WIPO Standard ST.16 if possible. 6Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by
`37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application
`form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this
`burden, should be sent to the Chief Information Officer, US. Patent and Trademark Office, PO. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED
`FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.0. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`

`

`Approved for use through 11/30/2020. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Substitute for form 1449/PTO
`_
`
`Complete if Known
`
`4315.0020001/TJS/THN
`
`—16/474,461
`INFORMATION DISCLOSURE —December28e 20”
`First Named Inventor
`GARCIA COLLAZO, Ana Maria
`MUM,
`1629
`To Be Assigned
`Attorney Docket Number
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`.—
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Examin
`er
`Initials*
`
`Cite
`No.1
`
`Include name ofthe author(in CAPITAL LETTERS),titIe of the article(when appropriate), title of
`the item (book,magazine,journal,seria|,symposium,catalog,etc.),date,page(s),vqume-issue
`number(s),publisher, city and/or country where published.
`
`N
`
`
`
`NPL1
`
`NPL2
`
`NPL3
`
`NPL4
`
`NPL5
`
`NPL6
`
`NPL7
`
`NPL8
`
`BEUTLER E., et al., "Glucocerebrosidase Mutations in Gaucher Disease," Molecular Medicine
`1(1):82-92, BioMed Central, England, (1994).
`
`BOYD R.E., et al., "Pharmacological Chaperones as Therapeutics for Lysosomal Storage
`Diseases," Journal of Medicinal Chemistry 56(7):2705-2725, American Chemical Society,
`United States ( 2013).
`
`CARRASCO, M. P., et al., “Exploring the Molecular Basis of Q0 bc, Complex Inhibitors Activity
`to Find Novel Antimalarial Hits,” Mol. Inf. 0000: 1-12, DOI: 10.1002/minf.201300024, Wiley
`Online Library, Germany (2013).
`
`CAVASOTTO, C.N., et al., “Discovery of Novel Chemotypes to a G-Protein-Coupled Receptor
`through Ligand-Steered Homology Modeling and Structure-Based Virtual Screening,” J. Med.
`Chem 51 :581-588, American Chemistry Society, United States (2008).
`
`COUTINHO, M.F., et al., "Less is More: Substrate Reduction Therapy for Lysosomal Storage
`Disorders," International Journal of Molecular Sciences 17(7):1065, MDPI, Switzerland (July
`2016) (22 pages).
`
`EKONOMIUK, D., et al., “Discovery ofa Non-Peptidic Inhibitor of West Nile Virus NS3 Protease
`by High-Throughput Docking,” PLOS 3(1):E356, Public Library of Science, United States (2009)
`(9 pages).
`
`GABRIELSEN, M., et al., “Molecular mechanism of serotonin transporter inhibition elucidated by
`a new flexible docking protocol,” European Journal of Medicinal Chemistry 47:24-37, Elsevier,
`Netherlands (2012).
`
`GLASS, L.S., et al., “Semi-automated high-throughput fluorescent intercalatordisplacement-
`based discovery of cytotoxic DNA binding agents from a large compound library,” Bioorganic &
`Medicinal Chemistry Letters 20:1685-1688, Elsevier Ltd., United Kingdom (2010).
`
`Examiner
`Signature
`
`
`
`Date
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include
`copy of this form with next communication to applicant. 1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language
`Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering,
`preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US. Patent and Trademark Office, PO. Box 1450, Alexandria, VA
`22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.0. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`

`

`Approved for use through 11/30/2020. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Substitute for form 1449/PTO
`_
`
`Complete if Known
`
`4315.0020001/TJS/THN
`
`—16/474,461
`INFORMATION DISCLOSURE —December28e 20”
`First Named Inventor
`GARCIA COLLAZO, Ana Maria
`MUM,
`1629
`To Be Assigned
`Attorney Docket Number
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`.—
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Examin
`er
`Initials*
`
`Cite
`No.1
`
`Include name ofthe author(in CAPITAL LETTERS),titIe of the article(when appropriate), title of
`the item (book,magazine,journal,seria|,symposium,catalog,etc.),date,page(s),vqume-issue
`number(s),publisher, city and/or country where published.
`
`N
`
`
`
`NPL9
`
`HUANG, W., et al., “IV4-Phenyl Modifications of NZ-(Z-hydroxyl)ethyl-6-(pyrrolidin-1-yl)1-1 ,3,5-
`triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential
`as chemical chaperones for Gaucher disease,” Bioorg. Med. Chem. Letters 17:5783-5789,
`Elsevier Ltd., United Kingdom (2007).
`
`NPL10
`
`International Preliminary Report on Patentability for Application No. PCT/IB2017/058477, mailed
`on December 05, 2018, 68 pages.
`
`NPL11
`
`International Search Report and Written Opinion for Application No. PCT/IB2017/058477,
`mailed on 03 May 2018, 9 pages.
`
`NPL12
`
`KAGAWA, C.M., et al., “Diuretic Effects of Formoguanamine and Other S—Triazines,” J.
`Pharmacol Exp. Ther. 124(4):318-323, Highwire, United States (1958).
`
`NPL13
`
`NPL14
`
`NPL15
`
`NPL16
`
`KATRITCH V., et al., “Structure-Based Discovery of Novel Chemotypes for Adenosine AZA
`Receptor Antagonists,” J. Med. Chem. 53:1799-1809, Journal of Medicinal Chemistry Article,
`American Chemical Society, United States (2010).
`
`KIM, S-Y., et al., “Predicted Ligands forthe Humand Urotensin-II G Protein-Coupled Receptor
`with Some Experimental Validation,” ChemMedChem 9:1732-1743, Wiley-VCH Verlag & Co.,
`Germany (2014).
`
`LU, P., et al., “Discovery ofa novel NEDD8 Activating Enzyme Inhibitor with Piperidin-4-amine
`Scaffold by Structure-Based Virtual Screening,” ACS Chemical Biology 11:1901-1907,
`American Chemical Society, United States (May 2016).
`
`MARUGAN, J.J., et al., “Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors
`with Chaperone Activity,” J. Med. Chem. 54:1033-1058, American Chemical Society, United
`States (2011).
`
`Examiner
`Signature
`
`
`
`Date
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include
`copy of this form with next communication to applicant. 1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language
`Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering,
`preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US. Patent and Trademark Office, PO. Box 1450, Alexandria, VA
`22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.0. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800—PTO-9199 (1-800—786—9199} and select option 2.
`
`

`

`Approved for use through 11/30/2020. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Substitute for form 1449/PTO
`_
`
`Complete if Known
`
`4315.0020001/TJS/THN
`
`—16/474,461
`INFORMATION DISCLOSURE —December28e 20”
`First Named Inventor
`GARCIA COLLAZO, Ana Maria
`MUM,
`1629
`To Be Assigned
`Attorney Docket Number
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`.—
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Examin
`er
`Initials*
`
`Cite
`No.1
`
`Include name ofthe author(in CAPITAL LETTERS),titIe of the article(when appropriate), title of
`the item (book,magazine,journal,seria|,symposium,catalog,etc.),date,page(s),vqume-issue
`number(s),publisher, city and/or country where published.
`
`N
`
`
`
`NPL17 MORSHED, M.N., et al., “Computational approach to the identification of novel Aurora-A
`inhibitors,” Bioorganic & Medicinal Chemistry 19:907-916, Elsevier Ltd., United Kingdom (2011).
`
`NPL18 MUWA, C., et al., “Structure-based virtual screening of novel, high-affinity BRD4 inhibitors,”
`Mol. BioSyst 10:2384-2397, Royal Society of Chemistry, United Kingdom (2014).
`
`NPL19
`
`NPL20
`
`PATNAIK S., et al., "Discovery, SAR, and Biological Evaluation of Noninhibitory Small Molecule
`Chaperones of Glucocerebrosidase," Journal of Medicinal Chemistry 55(12):5734-5748,
`American Chemical Society, United States (2012) (42 pages).
`
`POP, M. S., et al., “A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor
`Oncoprotein,” Molecular Cancer Therapeutics 13(6):1492-1502, American Association for
`Cancer Research, United States (2014).
`
`NPL21
`
`SHAPIRO, S. L., et al., “Guanamines. ll. Oxyalkyguanamine Anticonvulsants,” J. Am. Chem.
`Soc. 81(1):3996-4000, American Chemistry Society, United States (1959).
`
`NPL22
`
`SHAPIRO, S. L., et al., “Guanamines. V. ChIoromethylguanamines,” J. Am Chem. Soc.
`26(1):68—74, American Chemistry Society, United States (1961).
`
`NPL23
`
`SHAPIRO, S. L., et al., “Guanamines. VI. Aminomethylguanamines,” J. Am. Chem. Soc.
`26(1):?4-76, American Chemistry Society, United States (1961).
`
`NPL24
`
`SHEN, M., et al., “Discovery and optimization oftriazine derivatives as ROCK1 inhibitors:
`molecular docking, molecular dynamics simulations and free energy calculations,” Molecular
`BioSystems 9:361-374, Royal Society of Chemistry, Great Britain (2013).
`
`NPL25
`
`SIEBERT, M., et al., “Glucocerebrosidase is shaking up the synucleinopathies, “ Brain 137(Pt
`5):1304-1322, Oxford University Press, England (2014).
`
`Examiner
`Signature
`
`
`
`Date
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include
`copy of this form with next communication to applicant. 1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language
`Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering,
`preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US. Patent and Trademark Office, PO. Box 1450, Alexandria, VA
`22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.0. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`

`

`Approved for use through 11/30/2020. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Substitute for form 1449/PTO
`_
`
`Complete if Known
`
`4315.0020001/TJS/THN
`
`—16/474,461
`INFORMATION DISCLOSURE —December28e 20”
`First Named Inventor
`GARCIA COLLAZO, Ana Maria
`MUM,
`1629
`To Be Assigned
`Attorney Docket Number
`
`STATEMENT BY APPLICANT
`(Use as many sheets as necessary)
`
`.—
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Cite
`No.1
`
`Include name ofthe author(in CAPITAL LETTERS),titIe of the article(when appropriate), title of
`the item (book,magazine,journal,seria|,symposium,catalog,etc.),date,page(s),vqume-issue
`number(s),publisher, city and/or country where published.
`
` NPL32
`
`NPL26
`
`NPL27
`
`NPL28
`
`NPL29
`
`SOLANKEE, A., et al., “Synthesis of some new S-triazine based chalcones and their derivatives
`as potent antimicrobial agents,” European Journal of Medicinal Chemistry 42:510-518, Elsevier,
`Netherlands (2010).
`
`SVAJGER, U., et al., “Novel toll-like receptor4 (TLR4) antagonists identified by structure- and
`ligand-based virtual screening,” European Journal of Medicinal Chemistry 70:393-399, Elsevier,
`Netherlands (2013).
`
`TRAPERO, A., et al., “Potent Aminocyclitol Glucocerebrosidase Inhibitors are Subnanomolar
`Pharmacological Chaperones for Treating Gaucher Disease,” J. Med. Chem 55(9):4479-4488,
`American Chemistry Society, United States (2012) (33 pages).
`
`VIIRA, B., et al., “Design, discovery, modelling, synthesis, and biological evaluation of novel and
`small, low toxicity s—triazine derivatives as HIV-1 non-nucleoside reverse transcriptase
`inhibitors,” Bioorganic & Medicinal Chemistry 24:2519-2529, Elsevier Ltd., United Kingdom
`(April 2016).
`
`NPL30 Written Opinion for Application No. PCT/IBZO17/058477, mailed on July 5, 2018, 5 pages.
`
`NPL31
`
`YANG, L-L., et al., “Discovery of N6-phenyI-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine
`derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual
`screening and hit-to-Iead optimization,” European Journal of Medicinal Chemistry 56:30-38,
`Elsevier, Netherlands (2012).
`
`ZHENG, W., et al., “Three classes ofglucocerebrosidase inhibitors identified by quantitative
`high-throughput screening are chaperone leads for Gaucher disease,” PNAS 104(32):13192-
`13197, United States National Academy of Sciences, United States (2007).
`
`Examin
`er
`Initials*
`
`
`
`14070530_1.docx
`
`Examiner
`Signature
`
`
`
`Date
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include
`copy of this form with next communication to applicant. 1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language
`Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering,
`preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US. Patent and Trademark Office, PO. Box 1450, Alexandria, VA
`22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.0. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`